Promoting Excellence in the Field of Clinical Research through Education and Exchange
• 14,325+ Members
• 10,180+ "CCRP" Certified Clinical
• 40+ education programs, 2014
• 93 examination sites, 2013
The 23rd Annual Conference:
• September 19-21, 2014
• Marriott World Center Hotel,
Upcoming EventsSee All »
Newport Beach, CA
March 12-13, 2014
March 27-28, 2014
March 24 - 28, 2014
April 3-4, 2014
April 24 - 25, 2014
May 8 - 9, 2014
May 14 - 16, 2014
June 19-20, 2014
Oct. 9 & 10, 2014
Las Vegas, NV
Dec. 5 & 6, 2014
SOCRA programs meet industry criteria for ICH GCP investigator site personnel training
Clinical researchers who hold the SOCRA “CCRP,” Certified Clinical Research Professional designation, as well as those clinical researchers who complete specific SOCRA GCP courses (noted below), meet the minimum criteria for ICH GCP investigator site personnel training as identified by TransCelerate BioPharma member companies.
SOCRA education programs (in addition to “CCRP” certification) currently recognized by the companies listed below as appropriate GCP training for clinical trial site personnel include:
SoCRA “CCRP” Certification Preparation & GCP Review Course Scheduled for;
- March 17, 2014 in Singapore
- May 27, 2014 in San Francisco
- June 12, 2014 in Hollywood, Florida
- July 25, 2014 in Vancouver, British Columbia, Canada
- September 17, in Orlando Florida
- Plus additional locations to be posted on our web site
Clinical Site Coordinator/ Manager Workshop GCP for Coordinators, Research Associates, Study Nurses, Site Managers Scheduled for;
- April 3 and 4, 2014 in Vancouver, British Columbia, Canada
- July 10 and 11, 2014 in Chicago, IL
- November 14 and 15, 2014 in Nashville, Tennessee
Conducting Clinical Trials in Canada Scheduled for;
- May 8 and 9, 2014 in Toronto, ON, Canada
Clinical Investigator GCP & Trials Management Conference for Clinical Investigators and Key Research Staff Scheduled for;
- December 4 and 5, 2014, in Las Vegas, Nevada
Biogen Idec www.biogenidec.com
Boehringer Ingelheim www.boehringer-ingelheim.com/
Bristol-Myers Squibb www.bms.com
EMD Serono www.emdserono.com
Forest Laboratories, Inc. www.frx.com
Johnson & Johnson www.jnj.com
- March 17, 2014 in Singapore
New Guidance: Electronic Source Data in Clinical Investigations
This guidance addresses source data in clinical investigations used to fill the predefined fields in an electronic case report form (eCRF), according to the protocol. The guidance discusses the following topics related to electronic source data:
- Identification and specification of authorized source data originators
- Creation of data element identifiers to facilitate examination of the audit trail by sponsors, FDA, and other authorized parties
- Ways to capture source data into the eCRF using either manual or electronic methods
- Clinical investigator(s) responsibilities with respect to reviewing and retaining electronic data
- Use and description of computerized systems in clinical investigations
2014 Human Protections Conference Agenda is Posted!!
The 2014 Protecting Human Research Participants: Legal, Ethical, and Practical Considerations Conference will be held in Baltimore MD, on April 24 & 25, 2014. The agenda is now posted. Please visit the course page for more information
*NEW* Pediatric Clinical Trials Conference
SOCRA held its first conference specific to conducting Pediatric Clinical Trials on February 20 - 21, 2014. Over 110 people attended the event. SOCRA plans to hold the conference again in February 2015.
This two day program is designed assist Research Professionals in improving their skills and their understanding of the responsibilities of conducting clinical research in the pediatric population. This program will cover the regulatory, financial, and ethical components of conducting clinical trials in the pediatric population. View »
Revised FDA Compliance Program Guidance Manual
We feel that you should be advised that FDA has issued (March 11, 2011) a revised Compliance Program Guidance Manual (CPGM) for FDA Staff, for inspections of Sponsors, Contract Research Organizations and Monitors (CP 7348.810). By reading this guidance, you will understand exactly what the FDA investigator will be seeking to verify. The guidance will help you to assure that your own practices, policies and procedures address all of the areas noted in Part 3 – Inspectional. Part 3 involves evaluation of the sponsor’s/CRO’s/monitor’s practices and procedures in order for FDA Investigators to determine compliance with applicable regulations.
SoCRA’s Clinical Research conferences and workshops all address the regulations, guidance and practices involved in clinical trials through lecture, case studies, and discussion.
SoCRA Annual Conference
FDA Clinical Trial Requirements
Site Management Workshops
Clinical Research Monitoring Workshops
Clinical Investigator Conference
AAHRPP’s Standard I.7.A.
Click Here for AAHRPP’s clarification of their Standard I.7.A. pertaining to IRB approval of protocols for Phase 1 trials, specifically the issue of whether an IRB can approve advertising, recruiting, and screening procedures to begin prior to the end of the 30-day FDA review period or prior notification from FDA.
FDA Requires New Informed Consent Elements
The Food and Drug Administration (FDA) is amending the current informed consent regulations (21 CFR Part 50) to require that informed consent documents and processes for applicable drug (including biological products) and device clinical trials include a specific statement that clinical trial information will be entered into a databank. The databank referred to in this final rule is the clinical trial registry databank maintained by the National Institutes of Health/National Library of Medicine (NIH/NLM) which was created by statute. The submission of clinical trial information to this data bank also is required by statute. This amendment to the informed consent regulations is required by the Food and Drug Administration Amendments Act of 2007 (FDAAA) and is designed to promote transparency of clinical research to participants and patients.
This rule is effective March 7, 2011. The compliance date of this final rule is March 7, 2012, for clinical trials that are initiated on or after the compliance date. See section III of the document for an additional explanation of the compliance date and required implementation of this final rule. See Federal Register: Informed Consent Elements for all details relating to this final rule.